Pathology after eculizumab in dense deposit disease and C3 GN.
Ontology highlight
ABSTRACT: Eculizumab might benefit C3 glomerulopathies mediated by dysregulation of the alternative complement pathway. Here, we report renal biopsy findings before and after eculizumab therapy in three patients with dense deposit disease and two with C3 GN. All pretreatment biopsies had glomerular and tubular basement membrane deposits that stained exclusively for C3 without significant Ig. After 1 year of therapy, there was reduction in active glomerular proliferation and neutrophil infiltration in three of five patients, consistent with effective C5 blockade, which prevents production of chemotactin C5a. One individual with mild mesangial disease had no significant change in activity or chronicity. One patient exhibited persistent activity and worsening chronicity despite therapy. Immunofluoresce
SUBMITTER: Herlitz LC
PROVIDER: S-EPMC3380652 | biostudies-literature | 2012 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA